why choose us

First received: November 06, 2023

Clinical Trial: Study Evaluating Treatment of Sacituzumab-govitecan for Patients With Metastatic Esophagogastric Adenocarcinoma

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Esophagogastric Adenocarcinoma

Study Type: INTERVENTIONAL


Official Title: A Phase Ib/II Single-arm, Multicenter Study of Sacituzumab-govitecan, a TROP-2 Targeting Antibody Linked With SN38, for Patients With Metastatic Esophagogastric Adenocarcinoma

Brief Summary: The study is a open-label, single-arm, multicenter, phase Ib/II trial assessing the efficacy of sacituzumab-govitecan for metastatic esophagogastric adenocarcinoma

Read more